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BIOCHEMICAL JOURNAL 
Urothelial bladder cancer is a major cause of morbidity and mortality worldwide, causing an 
estimated 150,000 deaths per year. Whilst non-muscle-invasive bladder tumours can be effectively 
treated, with high survival rates, many tumours recur, and some will progress to muscle-invasive 
disease with a much poorer long term prognosis. Thus there is a pressing need to understand the 
molecular transitions occurring within the progression of bladder cancer to an invasive disease. 
Tumour invasion is often associated with a down regulation of E-cadherin expression concomitant 
with a suppression of cell: cell junctions and decreased levels of E-cadherin expression have been 
reported in higher grade urothelial bladder tumours. We find that expression of E-cadherin in a panel 
of bladder cancer cell lines correlated with the presence of cell: cell junctions and the level of PAK5 
expression. Interestingly exogenous PAK5 has recently been described to be associated with cell: 
cell junctions and we now find that endogenous PAK5 is localised to cell junctions and interacts with 
an E-cadherin complex. Moreover, depletion of PAK5 expression significantly reduced junctional 
integrity. These data suggest a role for PAK5 in maintaining junctional stability and we find that in 
both our own patient samples and a commercially available datasets that PAK5mRNA levels are 
reduced in human bladder cancer compared to normal controls. Taken together this study proposes 
that PAK5 expression levels could be used as a novel prognostic marker for bladder cancer 
progression. 
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Summary statement : We report high PAK5 expression in bladder cancer cells that 
are connected with  significantly reduced expression in individual cells. Moreover, we 
localise PAK5 to cell: cell junctions. Our data points to the importance of PAK5 for 
junctional integrity.  
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Abstract 
Urothelial bladder cancer  is a major cause of morbidity and mortality worldwide, 
causing an estimated 150,000 deaths per year. Whilst non-muscle-invasive bladder 
tumours can be effectively treated, with high survival rates,  many tumours recur, 
and some will progress to muscle-invasive disease with a much poorer long term 
prognosis. Thus there is a pressing need to understand the molecular transitions 
occurring within the progression of bladder cancer to an invasive disease. Tumour 
invasion is often associated with a down regulation of E-cadherin expression 
concomitant with a suppression of cell: cell junctions and decreased levels of E-
cadherin expression have been reported in higher grade urothelial bladder tumours. 
We find that expression of E-cadherin in a panel of bladder cancer cell lines 
correlated with the presence of cell: cell junctions and the level of PAK5 expression. 
Interestingly exogenous PAK5 has recently been described to be associated with 
cell: cell junctions and we now find that endogenous PAK5 is localised to cell 
junctions and interacts with an E-cadherin complex. Moreover, depletion of PAK5 
expression significantly reduced junctional integrity. These data suggest a role for 
PAK5 in maintaining junctional stability and we find that in both our own patient 
samples and a commercially available datasets that PAK5mRNA levels are reduced 
in human bladder cancer compared to normal controls. Taken together this study 
proposes that PAK5 expression levels  could be used as a novel prognostic marker 
for bladder cancer progression.   
Introduction  
Urothelial bladder cancer (UCB) is a major cause of morbidity and mortality 
worldwide, causing an estimated 150,000 deaths per year 1. Approximately 75% of 
patients with bladder cancer present with non-muscle-invasive bladder cancer 
(NMIBC) that is either confined to the mucosa (stage Ta, CIS) or to the submucosa 
(stage T1), while further 25% of patients present with muscle-invasive bladder 
cancer (MIBC) 2. Non-muscle-invasive bladder tumours can be effectively treated in 
a bladder-conservative approach by transurethral resection and adjuvant intravesical 
therapy. Patients with non-muscle-invasive bladder cancer have good prognosis, 
with survival rates of up to 94% 3. However, as many as 50-70% of these superficial 
tumours can recur, and 20-30% progress to muscle-invasive disease within 5 years 
of treatment 4, 5. Further research to understand the cellular and molecular behaviour 
of urothelial cells leading to MIBC holds the promise of more effective markers and 
therapeutic targets for bladder cancer.  
 
Tumour invasion and progression in bladder cancer appear to be parts of 
multifactorial process, promoted by intracellular and micro-environmental changes 
that include the upregulation of N-Cadherin and the corresponding downregulation of 
E-cadherin 6-9 often referred to as a cadherin switch. Loss of  E-cadherin expression 
is also associated with epithelial to mesenchymal transition (EMT) a biological 
process during embryologic development where epithelial cells down regulate 
expression of E-cadherin and/or disassemble cell: cell junctions and become more 
migratory as they assume a mesenchymal cellular phenotype 10, 11. Adoption of EMT 
pathways has long been associated with tumour invasion, migration and metastasis 
12, 13 14. Decreased E-cadherin immune-reactivity was first described in bladder 
cancer in 1993 15. A number of studies then followed, which demonstrated cadherin 
switching in the setting of bladder cancer, associated with late stage, high grade 
disease 9, 16-19.  A detailed study using on cadherin switching using pT1 and T2-T3 
bladder tumours 19 demonstrated that N-Cadherin expressing bladder cancer 
progressed more rapidly, and the majority of T2-T3 tumours demonstrated no 
expression of E-cadherin. Furthermore, Bryan et al 9 investigated P-Cadherin in 153 
human bladder cancer specimens, and observed that in high grade, muscle invasive 
tumours, E-Cadherin expression was decreased, P-Cadherin expression was 
increased, and this cadherin switching was associated with worse bladder cancer 
specific survival. 
 
The presence of adherens junctions is a defining feature of all epithelial tissue 20, 21. 
The prototypical protein that forms the transmembrane core of adherens junctions is 
E-cadherin. Whilst the extracellular domain of E-Cadherin is responsible for 
homotypic, calcium-dependent interactions with E-cadherins on the surface of 
adjacent cells, the cytoplasmic domain of E-Cadherin interacts with the actin 
cytoskeleton via catenins 22, 23.  Rho family of GTPases; Rho, Rac and Cdc42 are 
well-known regulators of actin dynamics with important roles in adherens junctions 
involving cadherin-catenin complexes in epithelial cells 24. Activated Rho-GTPases 
bind to a variety of effectors that regulate these cytoskeletal dynamics, and p21-
activated kinases (PAKs) are one family of such effectors 25. In the decade following 
the cloning and characterisation of PAK1, additional members of the human PAK-
family began to emerge with the identification of PAK-isoforms 2-6. PAK family of 
kinases are architecturally similar and their structure can be divided into three main 
domains: an N-terminal PBD (p21-GTPase binding domain), a central region and a 
highly conserved C-terminal serine/threonine kinase domain 26, 27. PAKs are 
subdivided into two groups based on structural and functional features 28, 29; group-1 
consists of PAK1, PAK2 and PAK3, while group-2 consists of PAK4, PAK5 and 
PAK6. Although PAK1 has been implicated in the recurrence of urothelial cancer of 
the bladder 30 and progression of upper tract urothelial cancer 31, the role of other 
PAKs have not been well characterised in urothelial oncogenesis.  
 
Evidence for the role of group-2 PAKs in cell junctions is emerging, albeit poorly 
understood. One of the studies has demonstrated that Cdc42 regulates the apical 
junction formation in human bronchial epithelial cells through PAK4 32. PAK6, which 
was initially identified to be an androgen receptor protein, and  has recently be 
reported to be involved in cell: cell dissociation in response to HGF, independent of 
androgen receptor (AR) signalling 33 and is thought to drive colony escape 34. 
Mechanistically, a complex of PAK6/E-cadherin/IQGAP1 was identified as the cells 
dissociate in response to HGF35.  Group 2 member PAK5 has been shown to interact 
with p120-Catenin, an important component of the cadherin-catenin-complex at 
adherens junctions 36. In the study, PAK5 was shown to phosphorylate p120-catenin 
on Serine 288, but the effect of this interaction on the adherens junctions has not 
been assessed. Recent reports do suggest that GFP-tagged PAK5 can be localised 
to cell : cell junctions 34, 37, and it was suggested that PAK5 might regulate junctional 
integrity, however neither study considered bladder cancer cells. This study aims to 
establish the expression profile of PAK family proteins in bladder cancer samples 
and elucidate whether PAK5 plays a specific functional role in bladder cancer cells.  
 
  
Materials and Methods  
Cell culture 
Bladder cancer cell lines: RT4, RT112, T24, TCCSUP and 253J were gifts from 
Professor John Masters, University College London. Cell line authentication by STR 
analysis was performed on these cell lines. Bladder cancer cell lines RT4, RT112, 
T24, TCCSUP and 253J were cultured in RPMI-1640 medium supplemented with L-
glutamine and NaHCO3, 10% foetal bovine serum and 1% penicillin/streptomycin 
(100U/ml penicillin and 100g/ml streptomycin). Human embryonic kidney 293 
(HEK293) cells were cultured in DMEM supplemented with glucose (4500mg/L), L-
glutamine, NaHCO3, pyridoxine HCl, 10% foetal bovine serum and 1% 
penicillin/streptomycin (100U/ml penicillin and 100g/ml streptomycin). Cells were 
incubated at 37 0C in a humidified atmosphere of 5% CO2. Bladder cancer cell lines 
were transfected using X-tremeGENE HP (Sigma) according to the manufacturers 
protocol. HEK293 cells were transfected using a calcium phosphate according to the 
manufacturers protocol (Sigma).  
 
Antibodies and siRNA 
Control and PAK5 specific siRNA oligonucleotides were transfected into RT4 cells 
using Lipofectamine RNAiMAX (Invitrogen). The PAK5 targeting sequences and 
control siRNA were purchased from Qiagen (Qiagen, Skelton House, UK). PAK5 
=ATGGTGTGCACGTTTCATTAA or ATGATCTGGATCCGTATTATA; mouse anti-E-
cadherin was purchased from Zymed USA, mouse anti-GAPDH was purchased from 
Sigma, mouse andti-N-cadherin was purchased from Transduction Labs , USA, 
mouse anti-GFP was purchased from Roche, rabbit anti-PAK1 was purchased from 
Cell Signalling Technology, USA, rabbit anti-PAK6 from Gentex, USA, rabbit anti-HA 
and mouse anti-HSP90 were purchased from Santa Cruz Technology USA, In house 
rabbit anti-PAK4 has been previously described 38. In house rabbit anti- PAK5 was 
raised using peptide inoculation (Eurogentec Ltd.) using a synthetic peptide with the 
following sequence -YREKSLYGDDLDPYY- corresponding to aa146-160 of PAK5 
protein - this antibody specifically recognises PAK5 and does not cross react with 
PAK4 and PAK6  as tested by western analysis using overexpressed proteins 
(Figure S1A).  
 
Western blotting 
Cells were washed twice in PBS and lysed on ice in NP-40 lysis buffer: 0.5% v/v NP-
40, 30mM sodium pyrophosphate, 50 mM Tris-HCL 38 supplemented with a Protease 
inhibitor cocktail: 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 10 μg/ml lysates were 
centrifuged at 13000 x g for 10 minutes to remove cell debris. Gel sample buffer  
was added to the supernatant the sample boiled at 90ºC for 3 minutes. Samples 
were resolved by SDS-PAGE as previously described 38. Nitrocelluloase were 
incubated with primary antibodies at appropriate concentrations and HRP-
conjugated secondary antibodies (Dako Ltd).  Autoradiographs were quantified using 
ImageJ software.  
 
Immunoprecipitation 
Cells were lysed as previously described, 38. For immunoprecipitation experiments, 
cell lysates were pre-cleared with IgG coupled Protein A or G sepharose beads (GE 
healthcare) for 1 h at 4˚C. The pre-cleared lysates were then mixed with primary 
antibody overnight at 4˚C followed by 1 h incubation with protein A or G-sepharose 
beads. Alternatively lysates were incubated with GFP-Trap®_A and purified 
according to the manufacturers protocol (ChromTek, Germany)  The immune 
complexes were washed three times with lysis buffer and resuspended in 2x SDS 
loading buffer.  Proteins were resolved by SDS-PAGE as previously described 38. 
Autoradiographs were quantified using Image J software. 
 
Immunofluorescence  
Cells on coverslips were fixed with 4% PFA in PBS at room temperature and washed 
3 times with PBS. The cells were then permeabilised with 0.2% Triton X-100: PBS 
and washed 3 times with PBS. The cells were then blocked with 3% BSA in PBS and 
washed 3 times with PBS. Cells were then incubated with the required primary 
antibody for 2 hours, and washed 3 times with PBS. Finally, cells were incubated 
with Alexa Fluor® 488 or 568, (Mouse/Rabbit Dako Ltd.) as required. Actin co-
staining was achieved using Phalloidin of complementary fluorescent emission (Trit-
C/Rhodamine/488/633 Invitrogen , UK). For nuclear staining, DAPI (1:10000 in PBS) 
was added following secondary antibody incubation and the coverslips were 
incubated for further 5 minutes. Cells were then washed 2 times with PBS and once 
in ddH2O before being mounted on glass slides using 10L FluorSave reagent. 
Cells were imaged on an Olympus IX71 inverted microscope system or Nikon A1R 
Confocal Microscope system. 
 
Generation of PAK5 expression constructs  
Polymerase chain reaction amplification of PAK5 cDNA was performed using the 
GatewayTM Technology system (Invitrogen, UK). PAK5 wild-type plasmid (kind gift of 
Jonathan Chernoff, Fox Chase Cancer Centre) was used as the DNA template in the 
production of PAK5 DNA flanked by attB sequences (the addition of attB sequences 
was required to allow for subsequent cloning into GatewayTM vectors) as described 
in the manufacturers protocol to generate PAK5 entry clone . The PCR reaction was 
performed using Accuprime PFX Supermix DNA polymerase. In order to generate 
GFP-, RFP-, myc-, and HA-PAK5 expression plasmids, GatewayTM LR recombination 
reactions were performed between the pENTR (PAK5) entry clone and the selected 
destination vectors including modified pEGFP-C1 (Clontech, UK), pDEST mRFP, 
and pDEST myc (pRK5-myc) in accordance with the manufacturer’s instructions. 
 
Image processing and cell shape analysis 
Image J software was used to elucidate the morphology of each cell by manually 
drawing around individual cells and then processing the data to give a circularity 
score. The autoradiographs were saved as TIF files in Adobe Photoshop CS5 and 
ImageJ software was used to quantify desired protein levels. In this analysis system 
it was assumed that 0 is black and the maximal value is 255 at 8 bits per pixel. 
These values were then used to calculate the mean fold value.  
  
Real-time reverse transcription quantitative PCR 
Real-time quantitative PCR, based on the Amplifluor technology, was to quantify 
the mRNA expression level of Aurora kinases from above cDNA samples of breast 
tissues following the method previously reported39. The pairs of Q-PCR primers were 
designed with Beacon Designer software which include complementary sequence to 
universal Z probe (Intergen Inc., Oxford, United Kingdom). The pair Q-PCR primers 
sequences are shown in X. Real-time PCR was carried out using an IcyclerIQ 
(Bio-Rad, Hemel Hempstead, UK) kit with the following cycling conditions: 94°C for 
12 minutes, 60 cycles of 94°C for 15 seconds, 55°C for 40 seconds (the data capture 
step) and 72°C for 20 seconds. The transcripts levels were generated from an 
internal standard which was simultaneously amplified with the samples.  
  
Results 
Differential morphology of bladder cancer cell lines in vitro  
Many bladder cancer cell lines have been characterised and matched to represent 
clinical tumour stages and grades. The characterisation was based on their tumour 
of origin, cell morphology in culture, gene and protein expression,  tumorigenicity and 
xenograft morphology 40-45.  A number of cell lines were selected to represent 
urothelial cell lines at different stages of tumour progression, corresponding to well-
differentiated, moderately-differentiated and poorly-differentiated primary urothelial 
tumour. RT4 is a paradigm for well-differentiated bladder carcinoma. This cell line 
was established from primary bladder tumour 46, where the histological appearance 
of the original tissue cultured was of a well differentiated, low grade urothelial 
carcinoma of the bladder.  RT112 is a moderately-differentiated urothelial carcinoma 
cell line which originated from a histology grade-2 (G2) papillary bladder tumour. In 
steady state, RT112 cells retain the epithelial-like morphology, in which the cells 
grow in distinct colonies to form an epithelial sheet in 2D culture 47, 48.  T24 and 
TCCSUP cell lines both originated from poorly differentiated, high grade primary 
urothelial tumours 49-51. The cell line 253J originated from metastatic retroperitoneal 
lymph node of a male patient with high grade (historically grade-4) bladder tumour 
with lymph node, bone and cerebral metastasis 49, 51.  RT112 and RT4 cells both 
grew in distinct colonies which can form an epithelial sheet in 2-D, where the 
archetypal epithelial cell-cell junctions were conserved.  Accumulation of F-actin at 
the margins of cell-cell junctions was prominent in these cell lines (Figure 1A), which 
is also a phenotype commonly associated with epithelial cells 52.  Actin-based 
membrane protrusions such as filopodia or lamellapodia were rarely observed in 
RT4 cells when cultured in basal growth condition. T24, TCCSUP and 253J cells 
grow as detached cells in 2-D culture (Figure 1A).  Distinct formation of cell: cell 
adhesion characterised by accumulation of F-actin at cell contact margins was not 
seen in these cells lines, even when the margins of adjacent cell were in contact with 
another.  The differences in cell morphology suggested bladder tumour cells (T24, 
TCCSUP and 253J) had lost  their epithelial morphology. We would predict that 
these cells  have undergone epithelial to mesenchymal transition, whereas RT4 and 
RT112 cells still retained their epithelial morphology when cultured in basal growth 
conditions. Consistent with the epithelial cell morphology seen previously, RT4 and 
RT112 cells retained the protein expression of E-cadherin, with no detectable 
expression of N –cadherin under basal growth conditions (Figure 1B). Conversely, 
T24, TCCSUP and 253J cells have lost the protein expression of E-cadherin, and 
consistent with the archetypal cadherin switch model, have gained the expression of 
N-cadherin (Figure 1B). 
 
Differential integrity of E-cadherin mediated cell: cell junctions in bladder 
cancer cell lines 
Our expression and morphological analysis would predict that RT4 and RT112 cells 
would have E-cadherin mediated cell: cell junctions. We therefore sought to localise 
E-cadherin in RT112 and RT4 cells under basal growth conditions. In RT4 cells, the 
e-cadherin staining at cell-cell junction was uniform and evenly distributed to form 
distinct E-cadherin plaques along the areas of cell-cell contact margin (Figure 1C). 
However, the e-cadherin staining in RT112 cells displayed a more disrupted or 
‘zippered’ appearance, where multiple E-cadherin-containing punctae cluster at 
varying intensities along the contact margins (Figure 1C).  For cells forming 
epithelial sheets, three stages of cell-cell adhesion and colony formation have been 
proposed 22, 52, 53. Stage 1 corresponded with immature junction which loosely hold 
cells together. At stage 2, E-cadherin plaques develop at the edges of the contact, 
and at stage 3, the E-cadherin plaques cinch together to form multi-cellular vertices, 
further condensing the cell colonies, which indicated mature and stable cell-cell 
adherens junctions. The fluorescence of E-cadherin signal was plotted to represent 
immunofluorescence intensity at the region of cell-cell contact in both these cell lines 
(Figure 1Ci). The formation of continuous of  E-cadherin plaques at the margins of 
cell-cell contact in  RT4 cells were consistent with more established and mature cell-
cell junctions (stages 2-3), whereas the interrupted staining pattern in RT112 cells 
suggested less mature formation of epithelial cell-cell junctions(stages 1-2).  
 
Bladder cancer cells express multiple Group II PAKs with differential 
expression levels. 
Having characterised our panel of bladder cancer cell lines we then sought to 
establish the profile of group II PAK expression. Previous work has demonstrated 
that high expression of PAK1 at both the gene transcription and protein expression 
levels was associated with highest grade bladder cancer. Thus as a control we 
initially tested our panel of cells lines for the presence of PAK1 protein . 
Immunoblotting with a PAK1 specific antibody revealed  expression of PAK1 with 
high total protein levels  in RT4 and TCCSUP cells compared to the other cell lines 
examined (Figure 2A). However, whilst  PAK1 was differentially expressed, the 
protein levels of PAK1 per se did not show any direct correlation with the epithelial 
differentiation of the cell lines within this panel. We next tested for PAK4, PAK5 and 
PAK6 expression using isoform specific antibodies. Interestingly, whilst the 
expression profile of PAK4 and PAK6 across the cell lines was ubiquitous, there was 
no differentiation between the cell lines of highly invasive origin and low grade 
papillary origin (Figure 2B&C). In contrast using an in house PAK5 specific  antibody 
(Figure S1A) we found that PAK5 expression (Figure 2D) was restricted to those 
cells of epithelial morphology RT4 and RT112 that still expressed e-cadherin (Figure 
1B)  and exhibited junctional E-cadherin localisation (Figure 1C). Moreover, relative 
PAK5 expression was highest in RT4 cells which contain extremely mature junctions 
(Figure 1D). Furthermore we have observed the same expression profile in breast 
and pancreatic cancer cell lines where PAK5 is expressed in those cells with E-
cadherin positive junctions but not in those cells that do not form cell: cell contacts 
(Figure S1B).  
 
Endogenous PAK5 is localised at cell: cell junctions in bladder cancer cells 
Our data suggests that cells with higher levels of PAK5 expression are more likely to 
be colony forming. Interestingly it was recently reported that PAK5 could be localised 
to cell: cell junctions 34, 37 although this localisation was based on exogenous 
overexpression. Using our PAK5-specific antibody (Figure S1A) we were able to 
detect endogenous PAK5 at cell: cell junctions in both RT4 (Figure 3A) and RT112 
cells (Figure S1C).  Indeed, line scans revealed a strong correlation between PAK5 
staining and E-cadherin staining in these cells (Figure 3B).  
 
PAK5 interacts in the E-cadherin complex in bladder cancer cells 
The localisation of endogenous PAK5 suggest that PAK5 may be an integral cell 
junction protein. We therefore tested whether PAK5 and E-cadherin were in a protein 
complex in RT4 bladder cancer cells. We were able to demonstrate that endogenous 
E-cadherin is present in an endogenous immunoprecipitation of PAK5 but not in the 
control sample. Equally we were able to demonstrate that endogenous PAK5 is 
present in an immunoprecipitation of endogenous E-cadherin (Figure 3C). 
Moreover, we could also demonstrate this interaction in RT112 cells (Figure S2A) 
Having established that PAK5 and E-cadherin are in a complex we proceeded to 
dissect the interaction in more detail by establishing whether E-cadherin binds to the 
PAK5 N- or C- terminal. HA-tagged full length PAK5, HA-tagged PAK5-N-terminal 
and HA-tagged C-terminal PAK5 were co-expressed with GFP-E-cadherin in the 
HEK293 cell line to maximise protein production. GFP-E-cadherin was isolated from 
cell lysates using GFP-TRAP and the isolate tested for the presence of PAK5 
variants using an anti-HA antibody. Whilst full length PAK5 and N-terminal PAK5 
were clearly present in the E-cadherin isolate there was no evidence to suggest that 
C-terminal PAK5 could interact with E-cadherin.   
 
Depletion of PAK5 expression promotes junctional disruption  
The differential expression level of PAK5 in cells which formed colonies, taken 
together with the  localisation of PAK5 at cell: cell junctions and the interaction 
between PAK5 and E-cadherin lead us to speculate that PAK5 might play a role in 
junctional integrity. To test this hypothesis we depleted PAK5 expression in RT4 
cells using two different siRNA oligos. Maximal knockdown of PAK5 expression was 
achieved 48 hours post treatment (Figure 4A) and PAK5 levels could be seen to be 
recovering at 72 hours (data not shown). Thus experiments were conducted within 
the 48 hour window. To ascertain the impact on junctional formation of loss of PAK5 
expression cell colonies were stained for E-cadherin (Figure 4B) and scored for the 
presence of less than or more than 50% adherent contact as defined in Figure 4C. 
There was significant reduction in cell: cell contact when RT4 cells were depleted of 
PAK5 expression using two specific siRNA oligos. Moreover, PAK5 depleted cells 
exhibited an increased circularity (Figure 4E) that would be expected from the 
definition criteria (Figure 4C). Importantly re-expression of siRNA resistant PAK5 
decreased circularity (Figure 4E and Figure S2C arrow versus arrowhead). Whilst 
we detected a loss of junctional integrity in our PAK5 depleted cells we did not see 
any evidence that PAK5 transcriptionally regulates E-cadherin expression. Global 
overexpression PAK5 does not elevate E-cadherin levels (Figure S2D). Moreover, 
exogenous expression of PAK5 in T24 cells did not promote E-cadherin expression 
nor the establishment of E-cadherin mediated junctions in cells of close proximity 
(Figure S2E arrowhead).  
PAK5 transcripts are significantly reduced in invasive disease. 
Taken together our data supports a role for PAK5 in stabilising cell: cell junctions via 
an interaction with the E-cadherin complex. We might therefore speculate that a loss 
of PAK5 expression might correlate with disease progression in bladder cancer. To 
test this hypothesis we  investigated a small cDNA library of human bladder tissue 
samples from Cardiff University which consisted of 34 samples of tumour tissue and 
18 samples of bladder tissue without any malignancy. We screened for expression of 
PAK1 and PAK5. The mRNA expression of PAK1 has been previously studied in 
bladder cancer and was shown to be associated with increased risk of tumour 
recurrence 30.  For quantitative analysis of PAK1 and PAK5 transcripts we employed 
a quantitative real-time polymerase chain reaction qRT PCR assay. The levels of the 
transcripts shown here are the ratios of respective PAK transcripts normalised to the 
level of GAPDH (Figure 5A). The values obtained from the assay indicated that in 
human patient samples, PAK1 transcripts were expressed at higher levels in 
malignant urothelium, compared to non malignant epithelium. Excitingly, the 
expression of PAK5 mRNA was lower in malignant epithelium compared to non-
malignant bladder tissue (Figure 5A). However, it was noted that the mRNA 
expression obtained in this assay varied greatly between each individual samples, 
even those within the subgroup (malignant/non-malignant), as indicated by the large 
error. Due to this variation, the differential expression of PAK1 and PAK5 detected 
whilst strongly suggesting an opposing trend  did not achieve statistical significance. 
As the mRNA expression profile for PAK5 obtained from bladder tissue samples was 
underpowered (Figure 5A)  we turned to a publicly available microarray data which 
included PAK5 expression in bladder cancer tissue on Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/) to expand our studies. One set of data was 
available which included the mRNA expression of PAK5 (referred to as PAK7 in the 
search) in 60 bladder tissue specimens with complete histopathological staging and 
grading of the tumour. The microarray data was linked to a publication on carcinoma 
in situ (CIS) of the bladder 54, in which the association between PAK5 and CIS was 
not identified, or discussed. The data in the microarray (GEO: GPL96, 213990_s_at 
(ID_REF), GDS1479, 57144) had been normalised using the Robust Multi-array 
Analysis (RMA). First, the data were analysed by comparing the mRNA transcription 
of PAK5 in normal urothelial specimen in this population (including normal urothelium 
obtained from patients with past history of urothelial cancer), and specimen from 
malignant urothelium of all grades and stages. PAK5 expression was higher in 
normal bladder tissue, and was downregulated in tumour tissues (Figure 5B), similar 
to the finding of PAK5 mRNA expression in Cardiff cohort (Figure 5A). In addition, 
the difference was statistically significant.  To further analyse of PAK5 expression in 
this dataset, we subdivided the tumours into the following 4 groups to indicate the 
risk of bladder cancer progression, and progressively poorer prognosis: Normal 
bladder tissue, Low risk non-muscle invasive bladder tumours (stage: pTa, grade: 2, 
no CIS), Moderate to high risk non-muscle invasive bladder tumours (stage pTa-1 
grade 2 with CIS, CIS, all stage pTa-1 grade 3 tumours), Muscle invasive bladder 
tumours (tumour stage T2 and above). Analysis of PAK5 mRNA levels according to 
these subgroups also indicated that PAK5 mRNA transcription were lower in tumours 
of all subgroups, compared to normal bladder tissues (Figure 5C)  Statistical 
analysis comparing the expression levels between the 4 subgroups (one-way 
analysis of variance, ANOVA) detected significant difference in PAK5 mRNA 
expression in bladder cancer compared to normal tissue (Figure 5C).  
Discussion  
We describe here a specific role for PAK5 in junctional integrity. We find that there is 
a positive correlation between PAK5 and E-Cadherin protein expression in well and 
moderately differentiated urothelial cancer cell lines (RT4 and RT112) which form 
cell-cell adherens junctions. Conversely, low or undetectable protein expression of 
PAK5 was associated bladder cancer cell lines with mesenchymal phenotype, 
lacking in cell-cell adherens junctions (T24, TCCSUP and 253J). We report that 
endogenous PAK5 is co-localised with E-Cadherin at cell-cell adherens junctions. 
Furthermore, we find that PAK5 directly interacts with the E-Cadherin complex and 
functions to stabilise junctions in colony forming cell lines. 
The clinical outcomes related to cancer diagnosis and treatment for many cancers 
have improved over the last decades but not so for bladder cancer, for which 
mortality has changed very little in the last few decades in England and Wales 55. 
Most patients with MIBC will still succumb to the disease associated with metastasis 
despite radical treatment regimens 56, 57, while patients with NMIBC are faced with 
lifelong surveillance due to the characteristic high recurrence rate of urothelial cancer 
58. Although the molecular events that characterise urothelial carcinoma are
increasingly defined and our understanding of the relevant pathways and networks 
has evolved, it is disappointing that no significant markers either for diagnosis of 
MIBC or NMIBC, let alone a marker able to risk stratify recurrence or relative 
prognosis have gained widespread acceptance and consistent validity. One of the 
proteins that can potentially differentiate urothelial tumours into low or high risk of 
disease progression is E-Cadherin. E-Cadherin is the major mediator of cell-cell 
junctions in epithelial tissues, and is expressed by most epithelial cells 59. Decreased 
E-cadherin immune-reactivity was first described in bladder cancer in 1993 15. A
number of studies then followed, which demonstrated cadherin switching in the 
setting of bladder cancer, associated with late stage, high grade disease 9, 16-19. A 
detailed study using on cadherin switching using pT1 and T2-T3 bladder tumours 19 
demonstrated that N-Cadherin expressing bladder cancer progressed more rapidly, 
and the majority of T2-T3 tumours demonstrated no expression of E-cadherin. In our 
study we find that PAK5 expression is high in cell lines with junctional formation but 
is almost entirely lost from those cells that no longer express E-cadherin. Moreover 
we find differential levels of PAK5 mRNA expression in human normal bladder tissue 
compared to carcinoma samples. Our findings are not in agreement with some 
previous reports that suggest PAK5 expression increases with malignant disease in 
colorectal 60, 61, gastric 62 and hepatocellular carcinoma 63.  However, on reviewing 
these publications, the sensitivity and specificity antibodies used to detect PAK5 
could have contributed significantly to the conflicting results. For example in the 
colorectal study 61, the isoform specificity of the polyclonal antibody has not been 
well described.  The epitope for antibody recognition was generated against 224-
amino acids N-terminal sequence of PAK5, and cross reaction with PAK4 was 
excluded. This could be significant as a recent classification of bladder cancer sub 
typing identified increased expression of PAK2 and PAK4 in high grade tumours of 
poor prognosis but not PAK564  in line with our findings.  Moreover,  a recent screen 
of 317 cancer cell lines for levels of PAK5 expression concluded that even those 
cells with relatively high PAK5 mRNA levels were low compared to PAK4 and PAK2 
37. We now propose that loss of PAK5 expression can be considered as a potential
novel prognostic marker of bladder cancer progression. 
Our results clearly indicate a localisation and functional significance for PAK5 at 
adherens junctions . Indeed, GFP-tagged PAK5 was also reported to be localised at 
cell: cell junctions in canine kidney cells37 and prostate cancer cells34. However the 
mechanism of function remains to be elucidated. We find that the N-terminal region 
of  PAK5 preferentially interacts with E-cadherin. Interestingly it has recently been 
reported that the N-terminal Cdc42 binding region of PAK6 is required to localise this 
protein to cell: cell junctions. Thus, it may be the case that binding of Cdc42 also 
localises PAK5 to cell: cell junctions. We and others34 , propose that PAK6 drives 
colony escape. Whilst work presented here supports a role for PAK5 in junction 
stabilisation. However, overexpression of GFP-tagged PAK5 was reported to disrupt  
cell: cell junctions in DU145 prostate cancer cells, thus opposing the role we propose 
here for PAK534. It should be noted that DU145 cells are not thought to express 
detectable levels of endogenous PAK534 and thus overexpression in this system 
might emulate a PAK6 rather than PAK5 physiological function as the two family 
members are structurally related.  In our work we have concentrated on working with 
endogenous PAK5. We found no evidence to suggest that PAK5 can regulate the 
expression level of E-cadherin. Rather, given that PAK5 is also reported to bind to 
p120 catenin we would predict a functional E-cadherin focussed unit at the cell 
junction that becomes destabilised when PAK5 is depleted. It would be of interest to 
monitor the localisation/mis-localisation of junctional proteins in PAK5 depleted cells. 
The presence of N-terminal PAK5 in a complex with E-cadherin  would suggest that 
PAK5 performs a scaffolding function within this unit but we cannot rule out a 
possible C-terminal substrate interaction with a junctional protein. Further work is 
required to characterise the  full interaction between PAK5 and adherens junction 
proteins.  
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Figure Legends  
Figure 1: Characterisation of E-cadherin expression status in bladder cancer 
cell lines 
A) Immunofluorescent phalloidin staining for F-actin in RT4, RT112, T24, 253J, and
TCCSUP cells at 40-60% subconfluent monolayer.  Cell co-stained for DAPI Scale 
bar = 10m. B) Cell lysates were prepared from RT4, RT112, T24, 253J, and 
TCCSUP cells. Lysates were probed for expression of E-cadherin/N-cadherin and 
GAPDH was used as a loading control. C) RT4 and RT112 cells were stained for E-
cadherin Ci) Immunofluorescence and line scan of E-cadherin staining at cell: cell 
junction of RT4  and RT112  cells. The boxes approximately register the edges of the 
contact plotted for fluorescence (arbitrary unit). Images shown  are representative of 
at least 3 independent experiments. Bar = 10μm.  
Figure 2: PAK family expression profile in bladder cancer cell lines 
Cell lysates were prepared from RT4, RT112, T24, 253J, and TCCSUP cells. 
Lysates were probed for expression of PAK1 (A) , PAK4 (B) and PAK6 (C) and 
PAK5 (D) in all experiments GAPDH was used as a loading control. Autoradiographs 
were scanned and quantified for expression from 3 independent experiments. 
Figure 3:PAK5 is localised at cell: cell junctions 
A) RT4 cells were stained for PAK5, DAPI and E-cadherin bar = 10mm B) co-
localisation analysis of PAK5 and E-cadherin signal using confocal line scanning. C) 
immunoprecipitation experiments isolating endogenous E-cadherin or endogenous 
PAK5 and probing for presence of PAK5 or E-cadherin in RT4 cells. Whole cell 
lysates (WCL) also probed for E-cadherin/PAK5 for size comparison. D) HEK293 
cells were transfected with GFP-Ecadherin and HA- PAK5 derivatives as indicated. 
GFP-E-cadherin was isolated by GFP-TRAP reagents and probed for the presence 
of HA-tagged PAK5 derivatives. Whole cell lysates of input were also probed (input) 
to confirm double transfection Heat Shock protein 90 (HSP90) was used as a loading 
control.  
Figure 4: Loss of PAK5 expression modulates cell junction integrity 
A) RT4 cells were treated with control or PAK5 specific siRNA oligos (si63 and si70).
Cell lysates were harvested at 48 hours post treatment and probed for PAK5 and 
GAPDH as a loading control. Autoradiographs were scanned and quantified for 
expression from 3 independent experiments. B) RT4 cells were treated with control 
or PAK5 specific siRNA 70 oligos fixed 48 hours post treatment and stained for E-
cadherin and DAPI. Arrows indicate cells with <50% membranous cell: cell adherent 
contact C) illustration of scoring criteria for junctional integrity. D) Cell images from 
RT4 cells  treated with control or PAK5 specific siRNA oligos were scored as 
described in (C) E) individual cells control , treated with si63 or si70 or treated with 
si70 and transfected with siRNA resistant GFP-PAK5 were measured for circularity 
using ImageJ software.   
Figure 5:Differnetial PAK5 mRNA levels in patient samples 
A) Quantitative RT-PCR of human normal and bladder cancer samples expression
levels were normalised to the GAPDH signal. 34 samples of tumour tissues and 18 
samples from bladder tissues without any malignancy were screened for expression 
of PAK1 and PAK5 using primers detailed in Figure S2B. B) Data in the microarray 
(GEO: GPL96, 213990_s_at (ID_REF), GDS1479, 57144) dataset were analysed by 
comparing the mRNA transcription of PAK5 in normal urothelial specimen in this 
population (including normal urothelium obtained from patients with past history of 
urothelial cancer), and specimen from malignant urothelium of all grades and stages. 
C) Dataset analysis comparing the expression levels between the 4 subgroups
indicated  (one-way analysis of variance, ANOVA). 
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Supplementary Figure Legends 
 
Figure S1 
A) The in house PAK5 antibody was tested against whole cell lysates 
overexpressing GFP-PAK4, GFP-PAK5 and GFP-PAK6. Only GFP-PAK5 was 
detected (panel 2) despite high levels of Expression (panel 1) B) Cell lysates form 
cells derived from other tissue types as indicated were probed for E-cadherin, PAK5 
and GAPDH expression. C) RT112 cells were fixed and stained for endogenous 
PAK5 , E-cadherin and DAPI bar = 10μm  
 
Figure S2 
A) immunoprecipitation experiments isolating endogenous E-cadherin or 
endogenous PAK5 and probing for presence of PAK5 or E-cadherin from RT112 
cells. Whole cell lysates (WCL) also probed for E-cadherin/PAK5 for size 
comparison. B) primer sequences used in quantitative RT-PCR (Figure 5) C) 
HEK293 cells were transfected with GFP alone or GFP-PAK5 and whole cell lysates 
probed for E-cadherin, PAK5 and GAPDH as a loading control. D) RT4 cells were 
treated with si70 siRNA specific to PAK5 and  subsequently transfected with GFP-
PAK5 si70 resistant. Cells were fixed and stained for F-actin. GFP-positive cells 
(arrow) are less circular than si70 treated cells (arrow head) and regain cell: cell 
contact length. E) T24 cells were transfected with GFP-PAK5 , fixed and stained for 
F-actin and E-cadherin. Arrow head indicates region of contact with lack of E-
cadherin positive staining Bar =10μm   


